Robert Nickelson
Hematology & Oncology · Shreveport, LANPI 1023019064
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,643 of the $3,721 with a category attached, or 71.0%. 34 manufacturers reported payments, led by Novartis at 33.7% of the total. Reporting peaked in 2019 at $2,766 and has fallen 98.6% since, to $38 in 2023. That places this record below the midpoint for hematology & oncology clinicians in LA, where the typical reported total is $4,451.
Across 192 payments — averaging $19.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- Merck$350
- Johnson & Johnson$257
- AstraZeneca$189
- Pfizer$152
- Takeda Pharmaceuticals U.S.A., Inc.$146
- plus $1K from 28 others
Across 4 payments — averaging $12,421 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$50K
What the payments were for
- Food & beverage$2,64371%
- Education$2096%
- Gifts$87023%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 42 | $1,254 |
| Merck | 23 | $350 |
| Johnson & Johnson(2 entities) | 13 | $257 |
| AstraZeneca(2 entities) | 12 | $189 |
| Pfizer | 14 | $152 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $146 |
| Amgen | 9 | $143 |
| Bard Peripheral Vascular, Inc. | 1 | $125 |
| E.r. Squibb & Sons, L.L.C. | 8 | $110 |
| Lilly USA, LLC | 8 | $110 |
| Eisai Inc. | 7 | $109 |
| Daiichi Sankyo Inc. | 8 | $106 |
| Bayer | 4 | $73 |
| Genentech USA, Inc. | 5 | $69 |
| Gilead | 5 | $67 |
| Sanofi | 3 | $57 |
| Bristol Myers Squibb | 3 | $47 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $38 |
| Regeneron Healthcare Solutions, Inc. | 2 | $31 |
| Incyte Corporation | 2 | $30 |
| Astellas Pharma US Inc | 2 | $25 |
| Puma Biotechnology, Inc. | 2 | $25 |
| Verastem, Inc. | 2 | $24 |
| Rigel Pharmaceuticals, Inc. | 1 | $23 |
| Boehringer Ingelheim | 1 | $22 |
| Tesaro, Inc. | 1 | $20 |
| Taiho Oncology, Inc. | 1 | $19 |
| GSK | 1 | $16 |
| AMAG Pharmaceuticals, Inc. | 1 | $16 |
| Exelixis Inc. | 1 | $15 |
| Advanced Accelerator Applications | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| EMD Serono, Inc. | 1 | $13 |
| Jazz Pharmaceuticals Inc. | 1 | $12 |
How this compares
$3,721 in reported general payments places this provider in the 45th percentile of 183 hematology & oncology providers in Louisiana.
Other hematology & oncology in Shreveport
- Prakash PeddiShreveport$405K
- Kevin GallagherShreveport$145K
- Maxwell McDonaldShreveport$123K
- Kirtan KotichaShreveport$45K
- Tharwat GhattasShreveport$25K
- Joyce FeaginShreveport$19K
- Richard MansourShreveport$16K
- Kavitha BeedupalliShreveport$15K
- Steven BoniolShreveport$14K
- Gary BurtonShreveport$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.